Results 211 to 220 of about 41,356 (289)
Skin Fragility and Hyperpigmentation in a Patient With HIV
Catalina Retamal +2 more
doaj +1 more source
Peristomal bullous pemphigoid: expanding the spectrum of localized presentations. [PDF]
Ramírez-Bravo F +5 more
europepmc +1 more source
Dupilumab‐Induced Psoriasis in a Patient with Bullous Pemphigoid
JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Nina Matthes +6 more
wiley +1 more source
Cumulative isotretinoin dosing, treatment response and acne relapse: A randomized controlled trial
In this randomized controlled trial, cumulative isotretinoin doses of 120 and 150 mg/kg showed similar relapse rates at 12 months. Both regimens achieved substantial and comparable reductions in inflammatory acne lesions across the face, chest and back.
Ruggero Cascio Ingurgio +16 more
wiley +1 more source
Stick-Slip Delamination of Monolayer MoS<sub>2</sub> from SiO<sub>2</sub> under Ambient Humidity. [PDF]
Haartsen S, Bampoulis P.
europepmc +1 more source
JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Aikaterini Kyriakou +7 more
wiley +1 more source
Updated S2k hidradenitis suppurativa (HS) guidelines provide expert consensus on diagnosis, assessment and comorbidities. Expanded substantially since the 2015 version, they reflect rapid growth in HS literature and aim to improve generalist‐level patient care through evidence‐informed, consensus‐based guidance.
G. B. E. Jemec +36 more
wiley +1 more source
Regression Equation for Predicting Source Strength Detection Rate in Iodine-125 Seed Brachytherapy. [PDF]
Takanashi M +6 more
europepmc +1 more source
Immune‐related adverse events with mogamulizumab in cutaneous T‐cell lymphoma: A multicentre study
In a nationwide multicentre study of 403 patients with cutaneous T‐cell lymphoma treated with mogamulizumab, non‐MAR immune‐related adverse events were reported in 8.4% of patients across responding centres. These events were diverse, sometimes severe or persistent, and could occur late during mogamulizumab treatment.
David Neubauer +28 more
wiley +1 more source
Recurrent Bullous Pemphigoid: A Case Report. [PDF]
Gowda Venkatesha RR +4 more
europepmc +1 more source

